A Phase 1a Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of OMP-336B11 Administered as a Single Agent to Subjects With Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2018
At a glance
- Drugs OMP 336B11 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors OncoMed Pharmaceuticals
- 08 Mar 2018 According to an Oncomed media release, company is planning to present the data from this study in 2019.
- 13 Sep 2017 According to an Oncomed media release, the first patient has been dosed in this trial. Kyriakos Papadopoulos is the lead investigator of this trial.
- 13 Sep 2017 Status changed from planning to recruiting, according to an Oncomed media release.